{
    "clinical_study": {
        "@rank": "99194", 
        "arm_group": [
            {
                "arm_group_label": "PEX168 50 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 50 microgram qw sc. and the medication continued for 8 weeks"
            }, 
            {
                "arm_group_label": "PEX168 100 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 100 microgram qw sc. and the medication continued for 8 weeks"
            }, 
            {
                "arm_group_label": "PEX168 200 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 200 microgram qw sc. and the medication continued for 8 weeks"
            }, 
            {
                "arm_group_label": "PEX168 300 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 300 microgram qw sc. and the medication continued for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo qw sc. and the medication continued for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1)\n      analogue that created on the basis of the Exenatide and modified by polyethylene glycol\n      (PEG).\n\n      This study aims to evaluate the PK, PD and safety by 8-week continuous treatment of PEX168."
        }, 
        "brief_title": "A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. aged 20-65 years old, male or female, diagnosis of type 2 diabetes according to the\n             1999 WHO criteria more than 3 months.\n\n          2. HbA1C 7.0-10.0% and fasting plasma glucose 7.0-10.0 mmol/L after treatment of diet,\n             exercise or a single oral hypoglycemic agents (metformin , glimepiride or\n             pioglitazone).\n\n          3. unused insulin within 3 months prior to the enrollment.\n\n          4. Body mass index within the range from 19 to 35, and body weight does not changes\n             exceeding 10% in the past 3 months.\n\n          5. Normol liver, kidney, heart function.\n\n          6. Willing to use physical means of contraception during the trial stage.\n\n          7. voluntarily to participate in the study.\n\n        Exclusion Criteria:\n\n          1. 1 diabetes.\n\n          2. used GLP-1, GLP-1 analogs or DPP-4 inhibitors in the past 3 months.\n\n          3. have diabetic ketoacidosis , diabetic hyperosmolar nonketotic coma patients with a\n             history\n\n          4. There is a history of severe hypoglycemia : such as low blood sugar cause drowsiness\n             , unconsciousness , nonsense , and even coma.\n\n          5. with severe diabetes complications ( renal , retinal , nerve , vascular disease).\n\n          6. has acute and chronic pancreatitis history ;\n\n          7. heart failure , unstable angina , severe arrhythmia, patients with a history of\n             myocardial infarction ;\n\n          8. There is a history of hypertension and blood pressure is not well controlled : SBP>\n             160mmHg and / or DBP> 95mmHg persons ;\n\n          9. severe chronic gastrointestinal disease ( active ulcer nearly six months ) or have\n             been affecting drug absorption in patients treated ;\n\n         10. There are obvious blood system diseases ;\n\n         11. There are other endocrine system diseases , such as hyperthyroidism , etc. ;\n\n         12. with severe trauma or surgery , severe infection ;\n\n         13. have mental illness , drug or other substance abuse or alcoholism ( drinking at least\n             2 times per week , more than 100g each drink ) ;\n\n         14. used any drugs that may affect the study , within 3 months before treatment as the\n             subjects participated in any clinical trials ;\n\n         15. within the past six months more than 400ml of blood loss (including blood , trauma or\n             other reasons ) ;\n\n         16. were receiving steroids or are receiving cancer treatment ;\n\n         17. has been prepared during pregnancy or pregnancy test in female patients ;\n\n         18. hepatitis B HBeAg , hepatitis C antibody positive , HIV antibody positive , syphilis\n             antibody positive .\n\n         19. skin test positive of PEX168;\n\n         20. The researchers considered any factors that the subject should not participate in\n             this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976858", 
            "org_study_id": "PEX168-I-03"
        }, 
        "intervention": {
            "arm_group_label": [
                "PEX168 50 microgram", 
                "PEX168 100 microgram", 
                "PEX168 200 microgram", 
                "PEX168 300 microgram", 
                "Placebo"
            ], 
            "description": "A injection administered subcutaneously", 
            "intervention_name": "PEX168", 
            "intervention_type": "Drug", 
            "other_name": "Polyethylene Glycol Loxenatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PEX168, diabetes, phase I", 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing"
                }, 
                "name": "Beijing tongren hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 8 Weeks Injection of Polyethylene Glycol Loxenatide", 
        "other_outcome": {
            "measure": "To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": {
            "affiliation": "Beijing Tongren Hospital", 
            "last_name": "Jinkui Yang, Ph.D, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine serum concentrations of PEX168", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976858"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To determin HbA1c levels of PEX168", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Beijing Tongren Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}